As big-game hunting goes, Sanofi chief executive Olivier Brandicourt is 0-for-2.
Two months ago, Sanofi appeared to be on the verge of acquiring Actelion Pharmaceuticals, which would have been a notable accomplishment for a couple of reasons: Johnson & Johnson had just backed out of negotiations to acquire Actelion and Sanofi had recently lost out on bidding for Medivation, a stinging defeat in a growth strategy that relies on big deals.
But something curious happened on the way to the negotiations.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect